U.S. stock futures mixed; Nvidia earnings spark little cheer
West Nadja, a director at Tempus AI , Inc. (NASDAQ:TEM), recently sold a significant portion of her holdings in the company, according to a filing with the Securities and Exchange Commission. On March 17, Nadja sold a total of 7,634 shares of Tempus AI’s Class A Common Stock, resulting in total proceeds of approximately $372,961. The transaction comes as TEM shares have shown mixed performance, with a strong YTD return of 42% despite recent volatility. According to InvestingPro analysis, the company’s market capitalization stands at $7.88 billion, with the stock currently appearing overvalued.
The sales occurred at prices ranging from $46.66 to $50.63 per share. Following these transactions, Nadja retains ownership of 30,071 shares in the company. The transactions were conducted under a pre-arranged trading plan established on December 3, 2024, in accordance with Rule 10b5-1. While Tempus AI has demonstrated strong revenue growth of 30% and maintains a FAIR financial health score, InvestingPro subscribers can access 7 additional key insights about the company’s financial position and growth prospects through the comprehensive Pro Research Report.
In other recent news, Tempus AI reported a 35.8% increase in revenue for the fourth quarter of 2024, reaching $700 million. Despite this robust growth, the company posted an earnings per share (EPS) of -0.18. Additionally, Tempus AI has projected revenue of $1.24 billion for 2025, including contributions from its recent acquisition of Ambry Genetics. The acquisition of Deep 6 AI was also announced, aimed at enhancing Tempus’s capabilities in supporting healthcare organizations with AI-driven research platforms.
Analyst firm Stifel maintained a Hold rating on Tempus AI’s stock, with a price target of $65, following these earnings results. Conversely, JPMorgan downgraded Tempus AI from Overweight to Neutral but raised its price target to $55, citing a slight revenue shortfall in the company’s non-core business. Tempus AI’s management anticipates core business growth of over 30% year-over-year, driven by advancements in its Genomics sector and data services.
The company’s strategic initiatives, such as the launch of the Olivia AI personal health app, further demonstrate its commitment to innovation. Tempus AI’s ongoing expansion and integration efforts, including the Deep 6 AI acquisition, are being closely monitored by investors. These developments highlight Tempus AI’s efforts to solidify its position in the healthcare technology sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.